Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Bavituximab |
| Trade Name | |
| Synonyms | Tarvacin |
| Drug Descriptions |
Tarvacin (bavituximab) is a monoclonal antibody that targets phosphatidylserine, which may induce an immune response targeting the tumor vasculature (PMID: 26550540, PMID: 31429027, PMID: 29767677). |
| DrugClasses | |
| CAS Registry Number | 648904-28-3 |
| NCIT ID | C49088 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Avelumab + Axitinib + Bavituximab | Avelumab Axitinib Bavituximab | 0 | 1 |
| Bavituximab | Bavituximab | 0 | 1 |
| Bavituximab + Capecitabine | Bavituximab Capecitabine | 0 | 1 |
| Bavituximab + Docetaxel | Bavituximab Docetaxel | 0 | 0 |
| Bavituximab + Pembrolizumab | Bavituximab Pembrolizumab | 0 | 3 |
| Bavituximab + Sorafenib | Bavituximab Sorafenib | 0 | 1 |
| Bavituximab + Temozolomide | Bavituximab Temozolomide | 0 | 1 |